Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Drug Profile

Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Alternative Names: Autologous CAR T-cell therapies - Poseida Therapeutics; Autologous CAR-based immuno-oncology therapeutics - Poseida; Autologous CAR-T therapies - Poseida Therapeutics; P PSMA 101

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Oct 2017 Preclinical data in Solid tumours released by Poseida Therapeutics
  • 11 Aug 2015 Preclinical trials in Multiple myeloma in USA (unspecified route)
  • 11 Aug 2015 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top